Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 337 · 2 trials · 7 indications
Adverse events and clinical laboratory abnormalities defined as DLTs.
Determine anti-tumor activity of AMG 337 in subjects with MET amplified gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1)
| Arm | Type | Description |
|---|---|---|
| Single arm | EXPERIMENTAL | - |
| Dose Escalation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AMG 337 | DRUG | Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1) |
Inclusion Criteria: * Able to self administer daily AMG 337 as a whole capsule * Male or female 20 years of age or over * Phase 1: Subjects must have a pathologically confirmed, advanced solid tumor for which the subjects have received prior therapy for advanced disease, for which no standard thera...
AMG 337 is an investigational small molecule being studied for the treatment of stomach neoplasms and advanced malignancy. It is being developed by Amgen Inc. for oncology indications. As of the available data, AMG 337 is in Phase 1 clinical development and has not been approved by regulatory authorities.
AMG 337 is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker AMGN. The drug is an investigational small molecule in Phase 1 clinical development for oncology indications, including stomach neoplasms and advanced malignancy.
AMG 337 is in Phase 1 clinical development. It is an investigational small molecule being studied for stomach neoplasms and advanced malignancy. The drug has not been approved by regulatory authorities and remains in clinical trials.
AMG 337 has been studied in two completed Phase 1 clinical trials. NCT01253707 enrolled 111 participants with advanced solid tumors in the United States. NCT02096666 enrolled 11 participants with stomach neoplasms in Japan. Both trials are completed, and no active trials are currently listed.
No alternative names for AMG 337 have been identified in the available data. The drug is referred to solely as AMG 337 in clinical trial records and development information.